|
US8053191B2
(en)
|
2006-08-31 |
2011-11-08 |
Westend Asset Clearinghouse Company, Llc |
Iterative nucleic acid assembly using activation of vector-encoded traits
|
|
US20140031250A1
(en)
|
2010-10-07 |
2014-01-30 |
David Tsai Ting |
Biomarkers of Cancer
|
|
WO2012078312A2
(en)
|
2010-11-12 |
2012-06-14 |
Gen9, Inc. |
Methods and devices for nucleic acids synthesis
|
|
US10457935B2
(en)
|
2010-11-12 |
2019-10-29 |
Gen9, Inc. |
Protein arrays and methods of using and making the same
|
|
BR112013024337A2
(pt)
|
2011-03-23 |
2017-09-26 |
Du Pont |
locus de traço transgênico complexo em uma planta, planta ou semente, método para produzir em uma planta um locus de traço transgênico complexo e construto de expressão
|
|
AU2012284365B2
(en)
|
2011-07-15 |
2017-04-20 |
The General Hospital Corporation |
Methods of transcription activator like effector assembly
|
|
EP2734621B1
(en)
|
2011-07-22 |
2019-09-04 |
President and Fellows of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
|
EP2748318B1
(en)
|
2011-08-26 |
2015-11-04 |
Gen9, Inc. |
Compositions and methods for high fidelity assembly of nucleic acids
|
|
EP3604555B1
(en)
|
2011-10-14 |
2024-12-25 |
President and Fellows of Harvard College |
Sequencing by structure assembly
|
|
ES2991004T3
(es)
|
2011-12-22 |
2024-12-02 |
Harvard College |
Métodos para la detección de analitos
|
|
WO2014163886A1
(en)
|
2013-03-12 |
2014-10-09 |
President And Fellows Of Harvard College |
Method of generating a three-dimensional nucleic acid containing matrix
|
|
GB201122458D0
(en)
*
|
2011-12-30 |
2012-02-08 |
Univ Wageningen |
Modified cascade ribonucleoproteins and uses thereof
|
|
WO2013139861A1
(en)
|
2012-03-20 |
2013-09-26 |
Luc Montagnier |
Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
|
|
US9150853B2
(en)
|
2012-03-21 |
2015-10-06 |
Gen9, Inc. |
Methods for screening proteins using DNA encoded chemical libraries as templates for enzyme catalysis
|
|
CN104603286B
(zh)
|
2012-04-24 |
2020-07-31 |
Gen9股份有限公司 |
在体外克隆中分选核酸和多重制备物的方法
|
|
EP3597741A1
(en)
|
2012-04-27 |
2020-01-22 |
Duke University |
Genetic correction of mutated genes
|
|
PL4289948T3
(pl)
|
2012-05-25 |
2025-06-02 |
The Regents Of The University Of California |
Sposoby i kompozycje do modyfikacji kierowanego na rna docelowego dna i do nakierowanej na rna modulacji transkrypcji
|
|
US9890364B2
(en)
|
2012-05-29 |
2018-02-13 |
The General Hospital Corporation |
TAL-Tet1 fusion proteins and methods of use thereof
|
|
CN104685116A
(zh)
|
2012-06-25 |
2015-06-03 |
Gen9股份有限公司 |
用于核酸组装和高通量测序的方法
|
|
WO2014059255A1
(en)
|
2012-10-12 |
2014-04-17 |
The General Hospital Corporation |
Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins
|
|
CN105142669B
(zh)
|
2012-12-06 |
2018-07-03 |
西格马-奥尔德里奇有限责任公司 |
基于crispr的基因组修饰和调控
|
|
WO2014093622A2
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
|
|
EP3434776A1
(en)
|
2012-12-12 |
2019-01-30 |
The Broad Institute, Inc. |
Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
|
|
WO2014093701A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
|
|
AU2014207618A1
(en)
|
2013-01-16 |
2015-08-06 |
Emory University |
Cas9-nucleic acid complexes and uses related thereto
|
|
AU2014214719B2
(en)
|
2013-02-07 |
2020-02-13 |
The General Hospital Corporation |
Tale transcriptional activators
|
|
KR20170108172A
(ko)
|
2013-03-14 |
2017-09-26 |
카리부 바이오사이언시스 인코포레이티드 |
핵산-표적화 핵산의 조성물 및 방법
|
|
US10760064B2
(en)
*
|
2013-03-15 |
2020-09-01 |
The General Hospital Corporation |
RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
|
|
IL289396B2
(en)
|
2013-03-15 |
2023-12-01 |
The General Hospital Coporation |
Using truncated guide rnas (tru-grnas) to increase specificity for rna-guided genome editing
|
|
US9828582B2
(en)
|
2013-03-19 |
2017-11-28 |
Duke University |
Compositions and methods for the induction and tuning of gene expression
|
|
JP2016522679A
(ja)
*
|
2013-04-04 |
2016-08-04 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
ＣＲＩＳＰＲ／Ｃａｓ系を用いたゲノム編集の治療的使用
|
|
MY197877A
(en)
|
2013-06-04 |
2023-07-22 |
Harvard College |
Rna-guided transcriptional regulation
|
|
US20140356956A1
(en)
*
|
2013-06-04 |
2014-12-04 |
President And Fellows Of Harvard College |
RNA-Guided Transcriptional Regulation
|
|
KR102307280B1
(ko)
*
|
2013-06-05 |
2021-10-01 |
듀크 유니버시티 |
Rna-가이드 유전자 편집 및 유전자 조절
|
|
CA2915837A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute, Inc. |
Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
|
|
EP3011033B1
(en)
|
2013-06-17 |
2020-02-19 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
|
|
EP3674411A1
(en)
|
2013-06-17 |
2020-07-01 |
The Broad Institute, Inc. |
Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
|
|
EP3597755A1
(en)
|
2013-06-17 |
2020-01-22 |
The Broad Institute, Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components
|
|
KR20240172759A
(ko)
|
2013-06-17 |
2024-12-10 |
더 브로드 인스티튜트, 인코퍼레이티드 |
간의 표적화 및 치료를 위한 ＣＲＩＳＰＲＣａｓ 시스템, 벡터 및 조성물의 전달 및 용도
|
|
US10011850B2
(en)
|
2013-06-21 |
2018-07-03 |
The General Hospital Corporation |
Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing
|
|
EP3019595A4
(en)
|
2013-07-09 |
2016-11-30 |
|
THERAPEUTIC USES OF A GENERIC CHANGE WITH CRISPR / CAS SYSTEMS
|
|
US20150044772A1
(en)
*
|
2013-08-09 |
2015-02-12 |
Sage Labs, Inc. |
Crispr/cas system-based novel fusion protein and its applications in genome editing
|
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
|
MX363842B
(es)
*
|
2013-08-22 |
2019-04-05 |
Du Pont |
Métodos para producir modificaciones genéticas en un genoma vegetal sin incorporar un marcador transgénico seleccionable, y composiciones de éstas.
|
|
US9322037B2
(en)
|
2013-09-06 |
2016-04-26 |
President And Fellows Of Harvard College |
Cas9-FokI fusion proteins and uses thereof
|
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
|
US9340800B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
Extended DNA-sensing GRNAS
|
|
EP3418379B1
(en)
|
2013-09-18 |
2020-12-09 |
Kymab Limited |
Methods, cells & organisms
|
|
US10584358B2
(en)
|
2013-10-30 |
2020-03-10 |
North Carolina State University |
Compositions and methods related to a type-II CRISPR-Cas system in Lactobacillus buchneri
|
|
JP2016536021A
(ja)
|
2013-11-07 |
2016-11-24 |
エディタス・メディシン，インコーポレイテッド |
ＣＲＩＳＰＲ関連方法および支配ｇＲＮＡのある組成物
|
|
US20150165054A1
(en)
*
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting caspase-9 point mutations
|
|
US9994831B2
(en)
*
|
2013-12-12 |
2018-06-12 |
The Regents Of The University Of California |
Methods and compositions for modifying a single stranded target nucleic acid
|
|
EP3653229A1
(en)
|
2013-12-12 |
2020-05-20 |
The Broad Institute, Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for genome editing
|
|
WO2015089364A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Crystal structure of a crispr-cas system, and uses thereof
|
|
EP3080271B1
(en)
*
|
2013-12-12 |
2020-02-12 |
The Broad Institute, Inc. |
Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
|
|
EP3080259B1
(en)
|
2013-12-12 |
2023-02-01 |
The Broad Institute, Inc. |
Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
|
|
CN105899658B
(zh)
|
2013-12-12 |
2020-02-18 |
布罗德研究所有限公司 |
针对hbv和病毒性疾病以及障碍的crispr-cas系统和组合物的递送、用途和治疗应用
|
|
WO2015089354A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders
|
|
EP3090044B1
(en)
*
|
2013-12-26 |
2021-11-03 |
The General Hospital Corporation |
Multiplex guide rnas
|
|
US10787654B2
(en)
|
2014-01-24 |
2020-09-29 |
North Carolina State University |
Methods and compositions for sequence guiding Cas9 targeting
|
|
DE212015000061U1
(de)
|
2014-02-11 |
2017-09-03 |
The Regents Of The University Of Colorado, A Body Corporate |
CRISPR-ermöglichtes Multiplex Genom Engineering
|
|
EP3957735A1
(en)
|
2014-03-05 |
2022-02-23 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa
|
|
ES2745769T3
(es)
|
2014-03-10 |
2020-03-03 |
Editas Medicine Inc |
Procedimientos y composiciones relacionados con CRISPR/CAS para tratar la amaurosis congénita de Leber 10 (LCA10)
|
|
US11339437B2
(en)
|
2014-03-10 |
2022-05-24 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290-associated disease
|
|
US11141493B2
(en)
|
2014-03-10 |
2021-10-12 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290-associated disease
|
|
WO2015148863A2
(en)
|
2014-03-26 |
2015-10-01 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating sickle cell disease
|
|
US12460231B2
(en)
|
2014-04-02 |
2025-11-04 |
Editas Medicine, Inc. |
Crispr/CAS-related methods and compositions for treating primary open angle glaucoma
|
|
WO2015155686A2
(en)
|
2014-04-08 |
2015-10-15 |
North Carolina State University |
Methods and compositions for rna-directed repression of transcription using crispr-associated genes
|
|
BR112016028023A2
(pt)
|
2014-05-30 |
2017-08-22 |
Univ Leland Stanford Junior |
Composições e métodos de administração de tratamentos para infecções virais latentes
|
|
KR102425438B1
(ko)
|
2014-06-23 |
2022-07-27 |
더 제너럴 하스피탈 코포레이션 |
서열결정에 의해 평가된 DSB의 게놈 전체에 걸친 비편향된 확인 (GUIDE-Seq)
|
|
EP3760208B1
(en)
|
2014-06-25 |
2024-05-29 |
The General Hospital Corporation |
Targeting human satellite ii (hsatii)
|
|
US20150376586A1
(en)
*
|
2014-06-25 |
2015-12-31 |
Caribou Biosciences, Inc. |
RNA Modification to Engineer Cas9 Activity
|
|
EP3167071B1
(en)
*
|
2014-07-09 |
2020-10-07 |
Gen9, Inc. |
Compositions and methods for site-directed dna nicking and cleaving
|
|
WO2016007347A1
(en)
|
2014-07-11 |
2016-01-14 |
E. I. Du Pont De Nemours And Company |
Compositions and methods for producing plants resistant to glyphosate herbicide
|
|
WO2016007839A1
(en)
|
2014-07-11 |
2016-01-14 |
President And Fellows Of Harvard College |
Methods for high-throughput labelling and detection of biological features in situ using microscopy
|
|
CA2956224A1
(en)
|
2014-07-30 |
2016-02-11 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
|
WO2016022866A1
(en)
|
2014-08-07 |
2016-02-11 |
Agilent Technologies, Inc. |
Cis-blocked guide rna
|
|
US10450584B2
(en)
|
2014-08-28 |
2019-10-22 |
North Carolina State University |
Cas9 proteins and guiding features for DNA targeting and genome editing
|
|
CA2956487A1
(en)
|
2014-09-12 |
2016-03-17 |
E. I. Du Pont De Nemours And Company |
Generation of site-specific-integration sites for complex trait loci in corn and soybean, and methods of use
|
|
WO2016049258A2
(en)
*
|
2014-09-25 |
2016-03-31 |
The Broad Institute Inc. |
Functional screening with optimized functional crispr-cas systems
|
|
US20170233762A1
(en)
*
|
2014-09-29 |
2017-08-17 |
The Regents Of The University Of California |
Scaffold rnas
|
|
EP3204496A1
(en)
*
|
2014-10-10 |
2017-08-16 |
Editas Medicine, Inc. |
Compositions and methods for promoting homology directed repair
|
|
GB201418965D0
(enExample)
|
2014-10-24 |
2014-12-10 |
Ospedale San Raffaele And Fond Telethon |
|
|
US9816080B2
(en)
|
2014-10-31 |
2017-11-14 |
President And Fellows Of Harvard College |
Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
|
|
US12180263B2
(en)
|
2014-11-06 |
2024-12-31 |
President And Fellows Of Harvard College |
Cells lacking B2M surface expression and methods for allogeneic administration of such cells
|
|
US11680268B2
(en)
|
2014-11-07 |
2023-06-20 |
Editas Medicine, Inc. |
Methods for improving CRISPR/Cas-mediated genome-editing
|
|
CN107109486B
(zh)
*
|
2014-11-14 |
2021-08-13 |
基础科学研究院 |
用于检测基因组中遗传剪刀的脱靶位点的方法
|
|
US11352666B2
(en)
|
2014-11-14 |
2022-06-07 |
Institute For Basic Science |
Method for detecting off-target sites of programmable nucleases in a genome
|
|
CN104531633A
(zh)
*
|
2014-11-18 |
2015-04-22 |
李云英 |
Cas9-scForkI融合蛋白及其应用
|
|
US10858662B2
(en)
|
2014-11-19 |
2020-12-08 |
Institute For Basic Science |
Genome editing with split Cas9 expressed from two vectors
|
|
US10900034B2
(en)
|
2014-12-03 |
2021-01-26 |
Agilent Technologies, Inc. |
Guide RNA with chemical modifications
|
|
WO2016090385A1
(en)
*
|
2014-12-05 |
2016-06-09 |
Applied Stemcell, Inc. |
Site-directed crispr/recombinase compositions and methods of integrating transgenes
|
|
CN113699116A
(zh)
|
2014-12-10 |
2021-11-26 |
明尼苏达大学董事会 |
用于治疗疾病的遗传修饰的细胞、组织和器官
|
|
EP3889260A1
(en)
|
2014-12-12 |
2021-10-06 |
The Broad Institute, Inc. |
Protected guide rnas (pgrnas)
|
|
EP3230452B1
(en)
*
|
2014-12-12 |
2025-06-11 |
The Broad Institute, Inc. |
Dead guides for crispr transcription factors
|
|
US20180179523A1
(en)
*
|
2014-12-18 |
2018-06-28 |
Integrated Dna Technologies, Inc. |
Crispr-based compositions and methods of use
|
|
EP3786296A1
(en)
*
|
2014-12-18 |
2021-03-03 |
Integrated Dna Technologies, Inc. |
Crispr-based compositions and methods of use
|
|
US10190106B2
(en)
*
|
2014-12-22 |
2019-01-29 |
Univesity Of Massachusetts |
Cas9-DNA targeting unit chimeras
|
|
CA2970370A1
(en)
|
2014-12-24 |
2016-06-30 |
Massachusetts Institute Of Technology |
Crispr having or associated with destabilization domains
|
|
WO2016114972A1
(en)
|
2015-01-12 |
2016-07-21 |
The Regents Of The University Of California |
Heterodimeric cas9 and methods of use thereof
|
|
LT3250691T
(lt)
*
|
2015-01-28 |
2023-09-11 |
Caribou Biosciences, Inc. |
Crispr hibridiniai dnr/rnr polinukleotidai ir naudojimo būdai
|
|
EP3250689B1
(en)
|
2015-01-28 |
2020-11-04 |
The Regents of The University of California |
Methods and compositions for labeling a single-stranded target nucleic acid
|
|
JP6929791B2
(ja)
*
|
2015-02-09 |
2021-09-01 |
デューク ユニバーシティ |
エピゲノム編集のための組成物および方法
|
|
AU2016220088C1
(en)
|
2015-02-18 |
2022-12-08 |
Iowa State University Research Foundation, Inc. |
Modification of transcriptional repressor binding site in NF-YC4 promoter for increased protein content and resistance to stress
|
|
WO2016141224A1
(en)
|
2015-03-03 |
2016-09-09 |
The General Hospital Corporation |
Engineered crispr-cas9 nucleases with altered pam specificity
|
|
US10450576B2
(en)
|
2015-03-27 |
2019-10-22 |
E I Du Pont De Nemours And Company |
Soybean U6 small nuclear RNA gene promoters and their use in constitutive expression of small RNA genes in plants
|
|
KR102888521B1
(ko)
|
2015-04-06 |
2025-11-19 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
Crispr/cas-매개 유전자 조절을 위한 화학적으로 변형된 가이드 rna
|
|
EP4019975A1
(en)
|
2015-04-24 |
2022-06-29 |
Editas Medicine, Inc. |
Evaluation of cas9 molecule/guide rna molecule complexes
|
|
CN107921148A
(zh)
|
2015-05-08 |
2018-04-17 |
哈佛学院校长同事会 |
通用供体干细胞和相关方法
|
|
CA2986310A1
(en)
|
2015-05-11 |
2016-11-17 |
Editas Medicine, Inc. |
Optimized crispr/cas9 systems and methods for gene editing in stem cells
|
|
AU2016270649B2
(en)
|
2015-05-29 |
2022-04-21 |
North Carolina State University |
Methods for screening bacteria, archaea, algae, and yeast using crispr nucleic acids
|
|
US20160346360A1
(en)
|
2015-05-29 |
2016-12-01 |
Agenovir Corporation |
Compositions and methods for cell targeted hpv treatment
|
|
US10117911B2
(en)
|
2015-05-29 |
2018-11-06 |
Agenovir Corporation |
Compositions and methods to treat herpes simplex virus infections
|
|
WO2016196655A1
(en)
|
2015-06-03 |
2016-12-08 |
The Regents Of The University Of California |
Cas9 variants and methods of use thereof
|
|
EP3302525A2
(en)
|
2015-06-05 |
2018-04-11 |
Novartis AG |
Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders
|
|
WO2016201047A1
(en)
|
2015-06-09 |
2016-12-15 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for improving transplantation
|
|
ES2802524T3
(es)
*
|
2015-06-10 |
2021-01-20 |
Firmenich & Cie |
Líneas celulares para el cribado de receptores de aroma y olor
|
|
KR20180034389A
(ko)
|
2015-06-12 |
2018-04-04 |
론자 워커스빌 아이엔씨. |
합성 전사인자를 이용한 핵 역분화 방법
|
|
ES2960226T3
(es)
|
2015-06-15 |
2024-03-01 |
Univ North Carolina State |
Métodos y composiciones para la administración eficiente de ácidos nucleicos y antimicrobianos basados en ARN
|
|
WO2016205759A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
|
|
MX392008B
(es)
|
2015-06-18 |
2025-03-21 |
Broad Inst Inc |
Mutaciones de la enzima crispr que reducen los efectos fuera del blanco
|
|
US11279928B2
(en)
*
|
2015-06-29 |
2022-03-22 |
Massachusetts Institute Of Technology |
Compositions comprising nucleic acids and methods of using the same
|
|
US11414657B2
(en)
|
2015-06-29 |
2022-08-16 |
Ionis Pharmaceuticals, Inc. |
Modified CRISPR RNA and modified single CRISPR RNA and uses thereof
|
|
EP3957731A1
(en)
|
2015-07-15 |
2022-02-23 |
Rutgers, The State University of New Jersey |
Nuclease-independent targeted gene editing platform and uses thereof
|
|
US10676735B2
(en)
|
2015-07-22 |
2020-06-09 |
Duke University |
High-throughput screening of regulatory element function with epigenome editing technologies
|
|
IL295616A
(en)
|
2015-07-31 |
2022-10-01 |
Us Health |
Adapted cells and treatment methods
|
|
US20180230450A1
(en)
*
|
2015-08-03 |
2018-08-16 |
President And Fellows Of Harvard College |
Cas9 Genome Editing and Transcriptional Regulation
|
|
WO2017024047A1
(en)
*
|
2015-08-03 |
2017-02-09 |
Emendobio Inc. |
Compositions and methods for increasing nuclease induced recombination rate in cells
|
|
CN108351350B
(zh)
|
2015-08-25 |
2022-02-18 |
杜克大学 |
使用rna指导型内切核酸酶改善基因组工程特异性的组合物和方法
|
|
US9926546B2
(en)
|
2015-08-28 |
2018-03-27 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
|
US9512446B1
(en)
|
2015-08-28 |
2016-12-06 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
|
WO2017040348A1
(en)
*
|
2015-08-28 |
2017-03-09 |
The General Hospital Corporation |
Engineered crispr-cas9 nucleases
|
|
WO2017040511A1
(en)
*
|
2015-08-31 |
2017-03-09 |
Agilent Technologies, Inc. |
Compounds and methods for crispr/cas-based genome editing by homologous recombination
|
|
WO2017044776A1
(en)
*
|
2015-09-10 |
2017-03-16 |
Texas Tech University System |
Single-guide rna (sgrna) with improved knockout efficiency
|
|
WO2017044843A1
(en)
*
|
2015-09-11 |
2017-03-16 |
The General Hospital Corporation |
Full interrogation of nuclease dsbs and sequencing (find-seq)
|
|
EP3786294A1
(en)
|
2015-09-24 |
2021-03-03 |
Editas Medicine, Inc. |
Use of exonucleases to improve crispr/cas-mediated genome editing
|
|
WO2017058751A1
(en)
|
2015-09-28 |
2017-04-06 |
North Carolina State University |
Methods and compositions for sequence specific antimicrobials
|
|
US9850484B2
(en)
|
2015-09-30 |
2017-12-26 |
The General Hospital Corporation |
Comprehensive in vitro reporting of cleavage events by sequencing (Circle-seq)
|
|
US11149281B2
(en)
|
2015-10-06 |
2021-10-19 |
Institute For Basic Science |
Method for producing genome-modified plants from plant protoplasts at high efficiency
|
|
US11970710B2
(en)
|
2015-10-13 |
2024-04-30 |
Duke University |
Genome engineering with Type I CRISPR systems in eukaryotic cells
|
|
EP4434589A3
(en)
|
2015-10-23 |
2025-05-14 |
President and Fellows of Harvard College |
Evolved cas9 proteins for gene editing
|
|
WO2017070598A1
(en)
|
2015-10-23 |
2017-04-27 |
Caribou Biosciences, Inc. |
Engineered crispr class 2 cross-type nucleic-acid targeting nucleic acids
|
|
EP3371329B1
(en)
|
2015-11-03 |
2026-03-25 |
President and Fellows of Harvard College |
Method and apparatus for volumetric imaging of a three-dimensional nucleic acid containing matrix
|
|
WO2017081288A1
(en)
|
2015-11-11 |
2017-05-18 |
Lonza Ltd |
Crispr-associated (cas) proteins with reduced immunogenicity
|
|
AU2016357319B2
(en)
|
2015-11-20 |
2022-03-10 |
Sage Science, Inc. |
Preparative electrophoretic method for targeted purification of genomic DNA fragments
|
|
JP6500293B2
(ja)
*
|
2015-11-25 |
2019-04-17 |
国立大学法人群馬大学 |
Ｄｎａメチル化編集用キットおよびｄｎａメチル化編集方法
|
|
KR102787119B1
(ko)
|
2015-11-30 |
2025-03-27 |
듀크 유니버시티 |
유전자 편집에 의한 인간 디스트로핀 유전자의 교정을 위한 치료용 표적 및 사용 방법
|
|
US11345931B2
(en)
|
2015-12-14 |
2022-05-31 |
President And Fellows Of Harvard College |
Cas discrimination using tuned guide RNA
|
|
WO2017112620A1
(en)
|
2015-12-22 |
2017-06-29 |
North Carolina State University |
Methods and compositions for delivery of crispr based antimicrobials
|
|
SG11201805217XA
(en)
*
|
2015-12-28 |
2018-07-30 |
Novartis Ag |
Compositions and methods for the treatment of hemoglobinopathies
|
|
MX2018008344A
(es)
|
2016-01-11 |
2018-12-06 |
Univ Leland Stanford Junior |
Proteinas quimericas y metodos para regular la expresion genica.
|
|
JP7012645B2
(ja)
|
2016-01-11 |
2022-01-28 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
キメラタンパク質および免疫治療の方法
|
|
WO2017136794A1
(en)
|
2016-02-03 |
2017-08-10 |
Massachusetts Institute Of Technology |
Structure-guided chemical modification of guide rna and its applications
|
|
EP3800249B1
(en)
|
2016-02-10 |
2022-06-22 |
The Regents of The University of Michigan |
Detection of nucleic acids
|
|
US20190249172A1
(en)
|
2016-02-18 |
2019-08-15 |
The Regents Of The University Of California |
Methods and compositions for gene editing in stem cells
|
|
US10538750B2
(en)
|
2016-02-29 |
2020-01-21 |
Agilent Technologies, Inc. |
Methods and compositions for blocking off-target nucleic acids from cleavage by CRISPR proteins
|
|
IL261516B2
(en)
|
2016-03-15 |
2025-04-01 |
Apse Inc |
Methods and compositions for the enhanced production of double-stranded RNA
|
|
JP2019515654A
(ja)
|
2016-03-16 |
2019-06-13 |
ザ ジェイ． デヴィッド グラッドストーン インスティテューツ |
肥満及び／又は糖尿病を処置するための方法及び組成物、並びに候補処置薬剤を識別するための方法及び組成物
|
|
EP3219799A1
(en)
|
2016-03-17 |
2017-09-20 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Conditional crispr sgrna expression
|
|
US11597924B2
(en)
|
2016-03-25 |
2023-03-07 |
Editas Medicine, Inc. |
Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
|
|
WO2017165862A1
(en)
|
2016-03-25 |
2017-09-28 |
Editas Medicine, Inc. |
Systems and methods for treating alpha 1-antitrypsin (a1at) deficiency
|
|
CN106701765A
(zh)
*
|
2016-04-11 |
2017-05-24 |
广东赤萌医疗科技有限公司 |
用于hiv感染治疗的多核苷酸及其制备药物应用
|
|
WO2017180694A1
(en)
|
2016-04-13 |
2017-10-19 |
Editas Medicine, Inc. |
Cas9 fusion molecules gene editing systems, and methods of use thereof
|
|
US20190127713A1
(en)
*
|
2016-04-13 |
2019-05-02 |
Duke University |
Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
|
|
CA3210120C
(en)
|
2016-04-25 |
2024-04-09 |
President And Fellows Of Harvard College |
Hybridization chain reaction methods for in situ molecular detection
|
|
CN107326046A
(zh)
*
|
2016-04-28 |
2017-11-07 |
上海邦耀生物科技有限公司 |
一种提高外源基因同源重组效率的方法
|
|
CN109475109B
(zh)
|
2016-05-20 |
2021-10-29 |
瑞泽恩制药公司 |
用于使用多个引导rna来破坏免疫耐受性的方法
|
|
US20190100732A1
(en)
|
2016-06-02 |
2019-04-04 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Assay for the removal of methyl-cytosine residues from dna
|
|
KR102811233B1
(ko)
*
|
2016-06-02 |
2025-05-29 |
시그마-알드리치 컴퍼니., 엘엘씨 |
프로그램가능한 dna 결합 단백질을 사용한, 표적화된 게놈 변형의 개선
|
|
US10767175B2
(en)
|
2016-06-08 |
2020-09-08 |
Agilent Technologies, Inc. |
High specificity genome editing using chemically modified guide RNAs
|
|
US20190177710A1
(en)
*
|
2016-06-15 |
2019-06-13 |
Toolgen Incorporated |
Method For Screening Target Specific Nuclease Using Multi-Target System Of On-Target And Off-Target And Use Thereof
|
|
CN109688820B
(zh)
|
2016-06-24 |
2023-01-10 |
科罗拉多州立大学董事会（法人团体） |
用于生成条形码化组合文库的方法
|
|
EP3474849B1
(en)
*
|
2016-06-27 |
2025-05-21 |
The Broad Institute, Inc. |
Compositions and methods for detecting and treating diabetes
|
|
US11359234B2
(en)
|
2016-07-01 |
2022-06-14 |
Microsoft Technology Licensing, Llc |
Barcoding sequences for identification of gene expression
|
|
WO2018005117A1
(en)
|
2016-07-01 |
2018-01-04 |
Microsoft Technology Licensing, Llc |
Storage through iterative dna editing
|
|
US20180004537A1
(en)
|
2016-07-01 |
2018-01-04 |
Microsoft Technology Licensing, Llc |
Molecular State Machines
|
|
AU2017295720B2
(en)
|
2016-07-13 |
2021-07-22 |
Vertex Pharmaceuticals Incorporated |
Methods, compositions and kits for increasing genome editing efficiency
|
|
CN109477086A
(zh)
*
|
2016-07-13 |
2019-03-15 |
陈奇涵 |
一种基因组dna特异性编辑方法和应用
|
|
EP4275747A3
(en)
|
2016-07-19 |
2024-01-24 |
Duke University |
Therapeutic applications of cpf1-based genome editing
|
|
CN109790527A
(zh)
*
|
2016-07-26 |
2019-05-21 |
通用医疗公司 |
普氏菌属和弗朗西斯氏菌属的CRISPR1(Cpf1)的变体
|
|
CN109789185A
(zh)
*
|
2016-07-28 |
2019-05-21 |
基础科学研究院 |
用于治疗眼部疾病的含cas9蛋白和向导rna的药物组合物
|
|
RU2721125C1
(ru)
|
2016-07-29 |
2020-05-18 |
Регенерон Фармасьютикалз, Инк. |
Мыши, содержащие мутации, вследствие которых экспрессируется укороченный на с-конце фибриллин-1
|
|
CA3032822A1
(en)
|
2016-08-02 |
2018-02-08 |
Editas Medicine, Inc. |
Compositions and methods for treating cep290 associated disease
|
|
JP7231935B2
(ja)
|
2016-08-03 |
2023-03-08 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
アデノシン核酸塩基編集因子およびそれらの使用
|
|
US11661590B2
(en)
|
2016-08-09 |
2023-05-30 |
President And Fellows Of Harvard College |
Programmable CAS9-recombinase fusion proteins and uses thereof
|
|
JP6799066B2
(ja)
|
2016-08-10 |
2020-12-09 |
株式会社ＧｅｎＡｈｅａｄ Ｂｉｏ |
真核細胞のゲノムの標的部位を改変する方法及び標的部位における検出対象核酸配列の存在又は非存在を検出する方法
|
|
WO2018034554A1
(ko)
*
|
2016-08-19 |
2018-02-22 |
주식회사 툴젠 |
인위적으로 조작된 신생혈관형성 조절 시스템
|
|
EP3500675A4
(en)
|
2016-08-19 |
2020-01-29 |
Whitehead Institute for Biomedical Research |
Methods of editing dna methylation
|
|
SG11201901364VA
(en)
|
2016-08-24 |
2019-03-28 |
Sangamo Therapeutics Inc |
Engineered target specific nucleases
|
|
CR20190098A
(es)
|
2016-08-24 |
2019-04-30 |
Sangamo Therapeutics Inc |
Regulación de la expresión génica usando nucleasas modificadas
|
|
WO2018039438A1
(en)
|
2016-08-24 |
2018-03-01 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
|
GB2569252A
(en)
|
2016-08-31 |
2019-06-12 |
Harvard College |
Methods of combining the detection of biomolecules into a single assay using fluorescent in situ sequencing
|
|
WO2018048194A1
(ko)
*
|
2016-09-07 |
2018-03-15 |
울산대학교 산학협력단 |
dCas9 단백질 및 표적 핵산 서열에 결합하는 gRNA를 이용한 핵산 검출의 민감도 및 특이도 향상용 조성물 및 방법
|
|
WO2018049073A1
(en)
*
|
2016-09-07 |
2018-03-15 |
Flagship Pioneering, Inc. |
Methods and compositions for modulating gene expression
|
|
JP2019532644A
(ja)
|
2016-09-30 |
2019-11-14 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Ｒｎａ誘導型核酸修飾酵素及びその使用方法
|
|
CN107880132B
(zh)
*
|
2016-09-30 |
2022-06-17 |
北京大学 |
一种融合蛋白及使用其进行同源重组的方法
|
|
WO2018064681A1
(en)
*
|
2016-09-30 |
2018-04-05 |
Poseida Therapeutics, Inc. |
Modified stem cell memory t cells, methods of making and methods of using same
|
|
US10669539B2
(en)
|
2016-10-06 |
2020-06-02 |
Pioneer Biolabs, Llc |
Methods and compositions for generating CRISPR guide RNA libraries
|
|
CN110462034A
(zh)
|
2016-10-07 |
2019-11-15 |
综合Dna技术公司 |
化脓链球菌cas9突变基因和由其编码的多肽
|
|
US11242542B2
(en)
|
2016-10-07 |
2022-02-08 |
Integrated Dna Technologies, Inc. |
S. pyogenes Cas9 mutant genes and polypeptides encoded by same
|
|
CN110290813A
(zh)
*
|
2016-10-14 |
2019-09-27 |
通用医疗公司 |
表观遗传学调控的位点特异性核酸酶
|
|
AU2017342543B2
(en)
|
2016-10-14 |
2024-06-27 |
President And Fellows Of Harvard College |
AAV delivery of nucleobase editors
|
|
EP4338799A3
(en)
|
2016-10-18 |
2024-06-05 |
Regents of the University of Minnesota |
Tumor infiltrating lymphocytes and methods of therapy
|
|
WO2018083606A1
(en)
|
2016-11-01 |
2018-05-11 |
Novartis Ag |
Methods and compositions for enhancing gene editing
|
|
US20180282722A1
(en)
*
|
2016-11-21 |
2018-10-04 |
Massachusetts Institute Of Technology |
Chimeric DNA:RNA Guide for High Accuracy Cas9 Genome Editing
|
|
JP2019535287A
(ja)
|
2016-11-22 |
2019-12-12 |
インテグレイテツド・デイー・エヌ・エイ・テクノロジーズ・インコーポレイテツド |
Ｃｒｉｓｐｒ／ｃｐｆ１システム及び方法
|
|
IL267024B2
(en)
*
|
2016-12-08 |
2023-12-01 |
Intellia Therapeutics Inc |
Adapted leader RNAs for genomic editing
|
|
WO2018111947A1
(en)
|
2016-12-12 |
2018-06-21 |
Integrated Dna Technologies, Inc. |
Genome editing enhancement
|
|
US20200149039A1
(en)
|
2016-12-12 |
2020-05-14 |
Whitehead Institute For Biomedical Research |
Regulation of transcription through ctcf loop anchors
|
|
CA3045134A1
(en)
|
2016-12-14 |
2018-06-21 |
Ligandal, Inc. |
Compositions and methods for nucleic acid and/or protein payload delivery
|
|
WO2018119010A1
(en)
|
2016-12-19 |
2018-06-28 |
Editas Medicine, Inc. |
Assessing nuclease cleavage
|
|
MY204487A
(en)
*
|
2016-12-22 |
2024-08-30 |
Intellia Therapeutics Inc |
Compositions and methods for treating alpha-1 antitrypsin deficiency
|
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
|
US20190382751A1
(en)
*
|
2016-12-28 |
2019-12-19 |
Ionis Pharmaceuticals, Inc. |
Modified crispr rna and uses thereof
|
|
CN110520163A
(zh)
*
|
2017-01-05 |
2019-11-29 |
新泽西鲁特格斯州立大学 |
独立于dna双链断裂的靶向基因编辑平台及其用途
|
|
WO2018129368A2
(en)
|
2017-01-06 |
2018-07-12 |
Editas Medicine, Inc. |
Methods of assessing nuclease cleavage
|
|
FI3565891T3
(fi)
|
2017-01-09 |
2023-07-04 |
Whitehead Inst Biomedical Res |
Menetelmiä geeniekspression muuttamiseksi häiritsemällä säätelysilmukoita muodostavia transkriptiotekijämultimeerejä
|
|
KR102084186B1
(ko)
*
|
2017-01-17 |
2020-03-03 |
기초과학연구원 |
Dna 단일가닥 절단에 의한 염기 교정 비표적 위치 확인 방법
|
|
WO2018136758A1
(en)
|
2017-01-23 |
2018-07-26 |
Regeneron Pharmaceuticals, Inc. |
Hsd17b13 variants and uses thereof
|
|
TW201839136A
(zh)
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
治療血色素異常症之組合物及方法
|
|
CN110312797A
(zh)
|
2017-02-10 |
2019-10-08 |
齐默尔根公司 |
组装和编辑用于多个宿主的多个dna构建体的模块化通用质粒设计策略
|
|
WO2018154096A1
(en)
|
2017-02-24 |
2018-08-30 |
Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin |
Method for re-expression of different hypermethylated genes involved in fibrosis, like hypermethylated rasal,1 and use thereof in treatment of fibrosis as well as kit of parts for re-expression of hypermethylated genes including rasal1 in a subject
|
|
EP3592768B1
(en)
|
2017-03-08 |
2024-12-25 |
The Regents of The University of Michigan |
Analyte detection
|
|
US11898179B2
(en)
|
2017-03-09 |
2024-02-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
|
CN110662556A
(zh)
|
2017-03-09 |
2020-01-07 |
哈佛大学的校长及成员们 |
癌症疫苗
|
|
JP2020510439A
(ja)
|
2017-03-10 |
2020-04-09 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
シトシンからグアニンへの塩基編集因子
|
|
WO2018170184A1
(en)
|
2017-03-14 |
2018-09-20 |
Editas Medicine, Inc. |
Systems and methods for the treatment of hemoglobinopathies
|
|
WO2018176009A1
(en)
|
2017-03-23 |
2018-09-27 |
President And Fellows Of Harvard College |
Nucleobase editors comprising nucleic acid programmable dna binding proteins
|
|
CN108660161B
(zh)
*
|
2017-03-31 |
2023-05-09 |
中国科学院脑科学与智能技术卓越创新中心 |
基于CRISPR/Cas9技术的制备无嵌合基因敲除动物的方法
|
|
US11867661B2
(en)
|
2017-04-07 |
2024-01-09 |
Sage Science, Inc. |
Systems and methods for detection of genetic structural variation using integrated electrophoretic DNA purification
|
|
US11484570B2
(en)
|
2017-04-14 |
2022-11-01 |
University Of Massachusetts |
Targeting cell tropism receptors to inhibit cytomegalovirus infection
|
|
BR112019021719A2
(pt)
|
2017-04-21 |
2020-06-16 |
The General Hospital Corporation |
Variantes de cpf1 (cas12a) com especificidade para pam alterada
|
|
AU2018254616B2
(en)
|
2017-04-21 |
2022-07-28 |
The General Hospital Corporation |
Inducible, tunable, and multiplex human gene regulation using crispr-Cpf1
|
|
EP3615672A1
(en)
|
2017-04-28 |
2020-03-04 |
Editas Medicine, Inc. |
Methods and systems for analyzing guide rna molecules
|
|
WO2018209158A2
(en)
|
2017-05-10 |
2018-11-15 |
Editas Medicine, Inc. |
Crispr/rna-guided nuclease systems and methods
|
|
US11560566B2
(en)
|
2017-05-12 |
2023-01-24 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
|
|
EP3630970A4
(en)
|
2017-05-25 |
2020-12-30 |
The General Hospital Corporation |
BASIC EDITORS WITH IMPROVED PRECISION AND SPECIFICITY
|
|
FI3635102T3
(fi)
|
2017-06-05 |
2025-10-28 |
Regeneron Pharma |
B4GALT1-variantteja ja niiden käyttöjä
|
|
CN108977442B
(zh)
*
|
2017-06-05 |
2023-01-06 |
广州市锐博生物科技有限公司 |
用于dna编辑的系统及其应用
|
|
EP3635104A1
(en)
|
2017-06-09 |
2020-04-15 |
Editas Medicine, Inc. |
Engineered cas9 nucleases
|
|
CA3065326A1
(en)
|
2017-06-14 |
2018-12-20 |
Wisconsin Alumni Research Foundation |
Modified guide rnas, crispr-ribonucleotprotein complexes and methods of use
|
|
MX2019015188A
(es)
|
2017-06-15 |
2020-08-03 |
Univ California |
Inserciones de adn no virales orientadas.
|
|
US10011849B1
(en)
|
2017-06-23 |
2018-07-03 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
|
US9982279B1
(en)
|
2017-06-23 |
2018-05-29 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
|
EP3645721A1
(en)
|
2017-06-30 |
2020-05-06 |
Novartis AG |
Methods for the treatment of disease with gene editing systems
|
|
EP3645021A4
(en)
|
2017-06-30 |
2021-04-21 |
Intima Bioscience, Inc. |
ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
|
|
KR102655021B1
(ko)
|
2017-07-11 |
2024-04-04 |
시그마-알드리치 컴퍼니., 엘엘씨 |
표적된 게놈 변형을 개선하기 위한 뉴클레오솜 상호작용 단백질 도메인 사용
|
|
WO2019014564A1
(en)
|
2017-07-14 |
2019-01-17 |
Editas Medicine, Inc. |
SYSTEMS AND METHODS OF TARGETED INTEGRATION AND GENOME EDITING AND DETECTION THEREOF WITH INTEGRATED PRIMING SITES
|
|
US11732274B2
(en)
|
2017-07-28 |
2023-08-22 |
President And Fellows Of Harvard College |
Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
|
|
AU2018309714A1
(en)
|
2017-07-31 |
2020-01-30 |
Regeneron Pharmaceuticals, Inc. |
Assessment of CRISPR/Cas-induced recombination with an exogenous donor nucleic acid in vivo
|
|
SG11201912235PA
(en)
|
2017-07-31 |
2020-01-30 |
Regeneron Pharma |
Cas-transgenic mouse embryonic stem cells and mice and uses thereof
|
|
EP3585160A2
(en)
*
|
2017-07-31 |
2020-01-01 |
Regeneron Pharmaceuticals, Inc. |
Crispr reporter non-human animals and uses thereof
|
|
EP3663310A4
(en)
|
2017-08-04 |
2021-08-11 |
Peking University |
TALE RVD SPECIFICALLY RECOGNIZING A DNA BASE MODIFIED BY METHYLATION AND CORRESPONDING APPLICATION
|
|
US11624077B2
(en)
|
2017-08-08 |
2023-04-11 |
Peking University |
Gene knockout method
|
|
EP3672612A4
(en)
|
2017-08-23 |
2021-09-29 |
The General Hospital Corporation |
GENETICALLY MODIFIED CRISPR-CAS9 NUCLEASES WITH MODIFIED PAM SPECIFICITY
|
|
WO2019139645A2
(en)
|
2017-08-30 |
2019-07-18 |
President And Fellows Of Harvard College |
High efficiency base editors comprising gam
|
|
ES2962277T3
(es)
|
2017-09-29 |
2024-03-18 |
Regeneron Pharma |
Roedores que comprenden un locus Ttr humanizado y métodos de uso
|
|
US11725228B2
(en)
|
2017-10-11 |
2023-08-15 |
The General Hospital Corporation |
Methods for detecting site-specific and spurious genomic deamination induced by base editing technologies
|
|
KR20200121782A
(ko)
|
2017-10-16 |
2020-10-26 |
더 브로드 인스티튜트, 인코퍼레이티드 |
아데노신 염기 편집제의 용도
|
|
CN107602707B
(zh)
*
|
2017-10-17 |
2021-04-23 |
湖北大学 |
一种特异性调节枯草芽孢杆菌外源基因表达的dcas9-ω融合蛋白及其应用
|
|
JP7101419B2
(ja)
|
2017-10-27 |
2022-07-15 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
内因性ｔ細胞受容体の標的置換
|
|
US20210180053A1
(en)
|
2017-11-01 |
2021-06-17 |
Novartis Ag |
Synthetic rnas and methods of use
|
|
WO2019089884A2
(en)
*
|
2017-11-01 |
2019-05-09 |
Editas Medicine, Inc. |
Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy
|
|
JP7423520B2
(ja)
*
|
2017-11-16 |
2024-01-29 |
アストラゼネカ・アクチエボラーグ |
Ｃａｓ９ベースノックイン方針の効力を改善するための組成物及び方法
|
|
US12406749B2
(en)
|
2017-12-15 |
2025-09-02 |
The Broad Institute, Inc. |
Systems and methods for predicting repair outcomes in genetic engineering
|
|
KR20210152597A
(ko)
*
|
2017-12-22 |
2021-12-15 |
(주)지플러스생명과학 |
키메라 게놈 조작 분자 및 방법
|
|
US12509492B2
(en)
|
2018-01-19 |
2025-12-30 |
Duke University |
Genome engineering with CRISPR-Cas systems in eukaryotes
|
|
CN109504711A
(zh)
*
|
2018-02-14 |
2019-03-22 |
复旦大学 |
基于CRISPR/cas9和过氧化物酶APEX2系统识别分析特异性基因组位点相互作用DNA的方法
|
|
US11718849B2
(en)
|
2018-02-19 |
2023-08-08 |
Agilent Technologies, Inc. |
Phosphopeptide-encoding oligonucleotide libraries and methods for detecting phosphorylation-dependent molecular interactions
|
|
WO2019165168A1
(en)
|
2018-02-23 |
2019-08-29 |
Pioneer Hi-Bred International, Inc. |
Novel cas9 orthologs
|
|
EP3765614A1
(en)
|
2018-03-14 |
2021-01-20 |
Editas Medicine, Inc. |
Systems and methods for the treatment of hemoglobinopathies
|
|
KR20240038811A
(ko)
|
2018-03-19 |
2024-03-25 |
리제너론 파마슈티칼스 인코포레이티드 |
CRISPR/Cas 시스템을 사용한 동물에서의 전사 조절
|
|
US20210155959A1
(en)
|
2018-04-06 |
2021-05-27 |
Children's Medical Center Corporation |
Compositions and methods for somatic cell reprogramming and modulating imprinting
|
|
WO2019204378A1
(en)
|
2018-04-17 |
2019-10-24 |
The General Hospital Corporation |
Sensitive in vitro assays for substrate preferences and sites of nucleic acid binding, modifying, and cleaving agents
|
|
CN112334577B
(zh)
|
2018-04-19 |
2023-10-17 |
加利福尼亚大学董事会 |
用于基因编辑的组合物和方法
|
|
WO2019213430A1
(en)
*
|
2018-05-03 |
2019-11-07 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods for nicking target dna sequences
|
|
CN108588123A
(zh)
*
|
2018-05-07 |
2018-09-28 |
南京医科大学 |
CRISPR/Cas9载体组合在制备基因敲除猪的血液制品中的应用
|
|
KR20250134703A
(ko)
|
2018-05-11 |
2025-09-11 |
빔 테라퓨틱스, 인크. |
프로그래밍가능한 염기 편집기 시스템을 이용하여 병원성 아미노산을 치환하는 방법
|
|
CN112654710A
(zh)
|
2018-05-16 |
2021-04-13 |
辛瑟高公司 |
用于指导rna设计和使用的方法和系统
|
|
US12157760B2
(en)
|
2018-05-23 |
2024-12-03 |
The Broad Institute, Inc. |
Base editors and uses thereof
|
|
EP3575396A1
(en)
*
|
2018-06-01 |
2019-12-04 |
Algentech SAS |
Gene targeting
|
|
CN110592141B
(zh)
*
|
2018-06-13 |
2023-07-07 |
中国科学院上海有机化学研究所 |
用于调控基因编辑效率的化合物及其应用
|
|
US12227776B2
(en)
|
2018-06-13 |
2025-02-18 |
Caribou Biosciences, Inc. |
Engineered cascade components and cascade complexes
|
|
US10227576B1
(en)
|
2018-06-13 |
2019-03-12 |
Caribou Biosciences, Inc. |
Engineered cascade components and cascade complexes
|
|
AU2019291918B2
(en)
|
2018-06-29 |
2025-06-12 |
Editas Medicine, Inc. |
Synthetic guide molecules, compositions and methods relating thereto
|
|
US12522807B2
(en)
|
2018-07-09 |
2026-01-13 |
The Broad Institute, Inc. |
RNA programmable epigenetic RNA modifiers and uses thereof
|
|
CA3105658A1
(en)
|
2018-07-13 |
2020-01-16 |
The Regents Of The University Of California |
Retrotransposon-based delivery vehicle and methods of use thereof
|
|
JP2021533773A
(ja)
|
2018-08-15 |
2021-12-09 |
ザイマージェン インコーポレイテッド |
ハイスループット代謝操作におけるＣＲＩＳＰＲｉの適用
|
|
WO2020041456A1
(en)
|
2018-08-22 |
2020-02-27 |
The Regents Of The University Of California |
Variant type v crispr/cas effector polypeptides and methods of use thereof
|
|
KR102712986B1
(ko)
|
2018-08-23 |
2024-10-07 |
상가모 테라퓨틱스, 인코포레이티드 |
조작된 표적 특이적 염기 편집기
|
|
EP3847251A1
(en)
|
2018-09-07 |
2021-07-14 |
Astrazeneca AB |
Compositions and methods for improved nucleases
|
|
US12264330B2
(en)
|
2018-10-01 |
2025-04-01 |
North Carolina State University |
Recombinant type I CRISPR-Cas system and uses thereof for killing target cells
|
|
US12264313B2
(en)
|
2018-10-01 |
2025-04-01 |
North Carolina State University |
Recombinant type I CRISPR-Cas system and uses thereof for genome modification and alteration of expression
|
|
WO2020072248A1
(en)
|
2018-10-01 |
2020-04-09 |
North Carolina State University |
Recombinant type i crispr-cas system
|
|
WO2020072253A1
(en)
|
2018-10-01 |
2020-04-09 |
North Carolina State University |
Recombinant type i crispr-cas system and uses thereof for screening for variant cells
|
|
WO2020076976A1
(en)
|
2018-10-10 |
2020-04-16 |
Readcoor, Inc. |
Three-dimensional spatial molecular indexing
|
|
US11407995B1
(en)
|
2018-10-26 |
2022-08-09 |
Inari Agriculture Technology, Inc. |
RNA-guided nucleases and DNA binding proteins
|
|
WO2020092453A1
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Nucleobase editors comprising geocas9 and uses thereof
|
|
US11434477B1
(en)
|
2018-11-02 |
2022-09-06 |
Inari Agriculture Technology, Inc. |
RNA-guided nucleases and DNA binding proteins
|
|
US11739320B2
(en)
|
2018-11-05 |
2023-08-29 |
Wisconsin Alumni Research Foundation |
Gene correction of Pompe disease and other autosomal recessive disorders via RNA-guided nucleases
|
|
AU2019374883A1
(en)
|
2018-11-09 |
2021-05-20 |
Inari Agriculture Technology, Inc. |
RNA-guided nucleases and DNA binding proteins
|
|
US12365888B2
(en)
|
2018-12-14 |
2025-07-22 |
Pioneer Hi-Bred International, Inc. |
CRISPR-Cas systems for genome editing
|
|
US11690362B2
(en)
|
2018-12-20 |
2023-07-04 |
Regeneran Pharmaceuticals, Inc. |
Nuclease-mediated repeat expansion
|
|
US20220106584A1
(en)
|
2019-01-14 |
2022-04-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and kits for generating and selecting a variant of a binding protein with increased binding affinity and/or specificity
|
|
WO2020154500A1
(en)
|
2019-01-23 |
2020-07-30 |
The Broad Institute, Inc. |
Supernegatively charged proteins and uses thereof
|
|
WO2020163396A1
(en)
|
2019-02-04 |
2020-08-13 |
The General Hospital Corporation |
Adenine dna base editor variants with reduced off-target rna editing
|
|
US12460230B2
(en)
|
2019-02-10 |
2025-11-04 |
The J. David Gladstone Institutes |
Modified mitochondrion and methods of use thereof
|
|
EP3935156A4
(en)
|
2019-03-07 |
2022-12-28 |
The Regents of The University of California |
CRISPR-CAS EFFECTIVE POLYPEPTIDES AND METHODS OF USE THEREOF
|
|
WO2020190932A1
(en)
|
2019-03-18 |
2020-09-24 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas screening platform to identify genetic modifiers of tau seeding or aggregation
|
|
SG11202108090XA
(en)
|
2019-03-18 |
2021-08-30 |
Regeneron Pharma |
Crispr/cas dropout screening platform to reveal genetic vulnerabilities associated with tau aggregation
|
|
MX2021011426A
(es)
|
2019-03-19 |
2022-03-11 |
Broad Inst Inc |
Metodos y composiciones para editar secuencias de nucleótidos.
|
|
AU2020256225B9
(en)
|
2019-04-03 |
2025-04-10 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for insertion of antibody coding sequences into a safe harbor locus
|
|
US11111504B2
(en)
|
2019-04-04 |
2021-09-07 |
Regeneron Pharmaceuticals, Inc. |
Methods for scarless introduction of targeted modifications into targeting vectors
|
|
WO2020206139A1
(en)
|
2019-04-04 |
2020-10-08 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized coagulation factor 12 locus
|
|
US20220162648A1
(en)
|
2019-04-12 |
2022-05-26 |
Astrazeneca Ab |
Compositions and methods for improved gene editing
|
|
WO2020214842A1
(en)
|
2019-04-17 |
2020-10-22 |
The Broad Institute, Inc. |
Adenine base editors with reduced off-target effects
|
|
EP3801011A1
(en)
|
2019-06-04 |
2021-04-14 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use
|
|
AU2020289581B2
(en)
|
2019-06-07 |
2024-11-21 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized albumin locus
|
|
CA3137765A1
(en)
|
2019-06-14 |
2020-12-17 |
Regeneron Pharmaceuticals, Inc. |
Models of tauopathy
|
|
CN114245803A
(zh)
|
2019-08-06 |
2022-03-25 |
儿童医疗中心有限公司 |
用于重构小神经胶质细胞的方法和组合物
|
|
EP3783104A1
(en)
*
|
2019-08-20 |
2021-02-24 |
Kemijski Institut |
Coiled-coil mediated tethering of crispr-cas and exonucleases for enhanced genome editing
|
|
CA3153980A1
(en)
|
2019-09-13 |
2021-03-18 |
Regeneron Pharmaceuticals, Inc. |
Transcription modulation in animals using crispr/cas systems delivered by lipid nanoparticles
|
|
CA3147643A1
(en)
|
2019-09-23 |
2021-04-01 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating hepatocyte nuclear factor 4-alpha (hnf4.alpha.) gene expression
|
|
US12435330B2
(en)
|
2019-10-10 |
2025-10-07 |
The Broad Institute, Inc. |
Methods and compositions for prime editing RNA
|
|
LT3812472T
(lt)
|
2019-10-21 |
2023-03-10 |
Albert-Ludwigs-Universität Freiburg |
Objektyviai nešališkas tyrimas in vitro sąlygomis, skirtas vienos arba daugiau tikslinių programuojamų nukleazių ląstelėje nespecifinės sąveikos aktyvumui profiliuoti (abnoba-seq)
|
|
US11331333B2
(en)
|
2019-11-08 |
2022-05-17 |
Georg-August-Universität Göttingen Stiftung Öffentichen Rechts, Universitätsmadizin |
Treatment of aberrant fibroblast proliferation
|
|
AU2020379046B2
(en)
|
2019-11-08 |
2025-03-13 |
Regeneron Pharmaceuticals, Inc. |
CRISPR and AAV strategies for X-linked juvenile retinoschisis therapy
|
|
US20230042198A1
(en)
*
|
2019-11-25 |
2023-02-09 |
La Jolla Institute For Immunology |
Methods and Compositions for Modulationg Heterochromatin Dysfunction, Genomic Instability, and Associate Conditions
|
|
WO2021108363A1
(en)
|
2019-11-25 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-mediated upregulation of humanized ttr allele
|
|
EP4073249A1
(en)
|
2019-12-11 |
2022-10-19 |
Intellia Therapeutics, Inc. |
Modified guide rnas for gene editing
|
|
CN111088357B
(zh)
*
|
2019-12-31 |
2022-09-20 |
深圳大学 |
针对escc的肿瘤标志物及其应用
|
|
US12312613B2
(en)
*
|
2020-01-24 |
2025-05-27 |
The General Hospital Corporation |
Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants
|
|
WO2021151085A2
(en)
|
2020-01-24 |
2021-07-29 |
The General Hospital Corporation |
Crispr-cas enzymes with enhanced on-target activity
|
|
WO2021155063A1
(en)
|
2020-01-29 |
2021-08-05 |
Readcoor, Llc |
Compositions and methods for analyte detection
|
|
JP2023519101A
(ja)
|
2020-02-12 |
2023-05-10 |
マサチューセッツ アイ アンド イヤー インファーマリー |
Ｒｐ１関連網膜変性症のハプロタイプに基づく処置
|
|
JP2023515671A
(ja)
|
2020-03-04 |
2023-04-13 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
免疫療法に対する腫瘍細胞の感作のための方法及び組成物
|
|
EP4114952A4
(en)
*
|
2020-03-05 |
2024-05-08 |
Board of Regents of the University of Nebraska |
Crispr/cas9 system for multistrain hiv-1 treatment
|
|
WO2021195079A1
(en)
|
2020-03-23 |
2021-09-30 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use
|
|
EP4133069A2
(en)
*
|
2020-04-08 |
2023-02-15 |
Astrazeneca AB |
Compositions and methods for improved site-specific modification
|
|
MX2022012683A
(es)
*
|
2020-04-09 |
2023-01-11 |
Verve Therapeutics Inc |
Edicion de bases de pcsk9 y metodos de uso de la misma para el tratamiento de enfermedades.
|
|
AU2021267334A1
(en)
*
|
2020-05-04 |
2022-12-22 |
Bluerock Therapeutics Lp |
Selection by essential-gene knock-in
|
|
WO2021224633A1
(en)
|
2020-05-06 |
2021-11-11 |
Orchard Therapeutics (Europe) Limited |
Treatment for neurodegenerative diseases
|
|
WO2021226558A1
(en)
|
2020-05-08 |
2021-11-11 |
The Broad Institute, Inc. |
Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
|
|
JP2023526007A
(ja)
|
2020-05-13 |
2023-06-20 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
β－ヘモグロビン異常症の処置のための塩基編集アプローチ
|
|
WO2021246165A1
(ja)
*
|
2020-06-03 |
2021-12-09 |
国立大学法人広島大学 |
Ｏａｓｉｓ遺伝子の脱メチル化のための核酸及びそれを用いた脱メチル化方法
|
|
IL298605A
(en)
*
|
2020-06-05 |
2023-01-01 |
Univ California |
Compositions and methods for epigenome editing
|
|
EP4179079A1
(en)
|
2020-07-10 |
2023-05-17 |
Horizon Discovery Limited |
Method for producing genetically modified cells
|
|
JP2023537093A
(ja)
|
2020-08-11 |
2023-08-30 |
イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブライ ユニバーシティ オブ エルサレム リミテッド |
Ｗｗｏｘ関連疾患の治療方法
|
|
US20220049303A1
(en)
|
2020-08-17 |
2022-02-17 |
Readcoor, Llc |
Methods and systems for spatial mapping of genetic variants
|
|
KR102674574B1
(ko)
*
|
2020-09-02 |
2024-06-13 |
한국과학기술연구원 |
Cas9을 위한 신규 tracrRNA 시스템
|
|
CN116391040A
(zh)
|
2020-10-13 |
2023-07-04 |
法国国家科学研究中心(Cnrs) |
结合接合和Crispr/Cas系统的靶向抗菌质粒及其用途
|
|
RU2762831C1
(ru)
*
|
2020-10-26 |
2021-12-23 |
Федеральное государственное бюджетное научное учреждение "Всероссийский научно-исследовательский институт сельскохозяйственной биотехнологии" (ФГБНУ ВНИИСБ) |
Молекула рнк-проводника для геномного редактирования протомоторной области гена vrn-a1 однодольных зерновых с применением системы crispr/cas9
|
|
CN112430622A
(zh)
*
|
2020-10-26 |
2021-03-02 |
扬州大学 |
一种FokI和dCpf1融合蛋白表达载体及其介导的定点基因编辑方法
|
|
WO2022120022A1
(en)
|
2020-12-02 |
2022-06-09 |
Regeneron Pharmaceuticals, Inc. |
Crispr sam biosensor cell lines and methods of use thereof
|
|
KR20220082186A
(ko)
|
2020-12-10 |
2022-06-17 |
한세준 |
유,무선 충전이 가능한 보조배터리형 uv-led살균기
|
|
JP2024501757A
(ja)
|
2021-01-05 |
2024-01-15 |
ホライズン・ディスカバリー・リミテッド |
遺伝子組換え細胞の製造方法
|
|
AU2022216614B2
(en)
|
2021-02-05 |
2026-03-05 |
Christiana Care Gene Editing Institute, Inc. |
Methods of and compositions for reducing gene expression and/or activity
|
|
US20240052372A1
(en)
|
2021-02-25 |
2024-02-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Allele-specific genome editing of the nr2e3 mutation g56r
|
|
KR102882704B1
(ko)
|
2021-03-03 |
2025-11-12 |
중앙대학교 산학협력단 |
CRISPR/Cas9 시스템을 이용한 유전체 단일염기 편집 방법 및 이의 용도
|
|
CN113846019B
(zh)
*
|
2021-03-05 |
2023-08-01 |
海南师范大学 |
一种海洋微拟球藻靶向表观基因组遗传调控方法
|
|
EP4095243A1
(en)
|
2021-05-25 |
2022-11-30 |
European Molecular Biology Laboratory |
System for hybridization-based precision genome cleavage and editing, and uses thereof
|
|
JP2024518793A
(ja)
|
2021-05-27 |
2024-05-02 |
アストラゼネカ・アクチエボラーグ |
向上した安定性を有するｃａｓ９エフェクタータンパク質
|
|
EP4352225A1
(en)
|
2021-06-10 |
2024-04-17 |
Intellia Therapeutics, Inc. |
Modified guide rnas comprising an internal linker for gene editing
|
|
WO2023010133A2
(en)
|
2021-07-30 |
2023-02-02 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of frataxin (fxn)
|
|
AU2022318664A1
(en)
|
2021-07-30 |
2024-02-29 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
|
|
WO2023023635A1
(en)
|
2021-08-20 |
2023-02-23 |
Wisconsin Alumni Research Foundation |
Nonviral generation of genome edited chimeric antigen receptor t cells
|
|
WO2023039586A1
(en)
|
2021-09-10 |
2023-03-16 |
Agilent Technologies, Inc. |
Guide rnas with chemical modification for prime editing
|
|
EP4409000A1
(en)
|
2021-09-28 |
2024-08-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Base editing approaches for the treatment of beta-hemoglobinopathies
|
|
EP4596697A3
(en)
|
2021-09-28 |
2025-08-27 |
Acrigen Biosciences |
Compositions and methods for nucleic acid modifications
|
|
WO2023052508A2
(en)
|
2021-09-30 |
2023-04-06 |
Astrazeneca Ab |
Use of inhibitors to increase efficiency of crispr/cas insertions
|
|
KR20240099259A
(ko)
|
2021-10-14 |
2024-06-28 |
아스널 바이오사이언시스, 인크. |
공동 발현된 shrna 및 논리 게이트 시스템을 갖는 면역 세포
|
|
CA3234809A1
(en)
|
2021-10-20 |
2023-04-27 |
Steven Goldman |
Isolated glial progenitor cells for use in the competition treatment of age-related white matter loss
|
|
EP4423271A2
(en)
|
2021-10-28 |
2024-09-04 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-related methods and compositions for knocking out c5
|
|
CA3237482A1
(en)
|
2021-11-03 |
2023-05-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Precise genome editing using retrons
|
|
AU2022382975A1
(en)
|
2021-11-03 |
2024-05-02 |
Intellia Therapeutics, Inc. |
Polynucleotides, compositions, and methods for genome editing
|
|
WO2023099591A1
(en)
|
2021-12-01 |
2023-06-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for increasing fetal hemoglobin content by editing the +55-kb region of the erythroid-specific bcl11a enhancer
|
|
KR20240117571A
(ko)
|
2021-12-08 |
2024-08-01 |
리제너론 파마슈티칼스 인코포레이티드 |
돌연변이 마이오실린 질환 모델 및 이의 용도
|
|
US20230279442A1
(en)
|
2021-12-15 |
2023-09-07 |
Versitech Limited |
Engineered cas9-nucleases and method of use thereof
|
|
WO2023137471A1
(en)
|
2022-01-14 |
2023-07-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
|
|
CA3247927A1
(en)
|
2022-01-14 |
2023-07-20 |
Tune Therapeutics, Inc. |
Compositions, systems and methods for programming T-lymphocyte phenotypes by targeted gene repression
|
|
WO2023141487A1
(en)
*
|
2022-01-20 |
2023-07-27 |
Inari Agriculture Technology, Inc. |
Improved soybean explant preparation and transformation
|
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
WO2023144104A1
(en)
|
2022-01-25 |
2023-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Base editing approaches for the treatment of βeta-thalassemia
|
|
JP2025508677A
(ja)
|
2022-02-02 |
2025-04-10 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ポンペ病の処置のための抗ＴｆＲ：ＧＡＡ及び抗ＣＤ６３：ＧＡＡの挿入
|
|
US20250152677A1
(en)
|
2022-02-14 |
2025-05-15 |
Institut National de la Santé et de la Recherche Médicale |
Treatment of liver cancers by disrupting the beta-catenin/tcf-4 binding site located upstreatm of meg3 in the dlk1/dio3 locus
|
|
EP4514981A2
(en)
|
2022-04-29 |
2025-03-05 |
Regeneron Pharmaceuticals, Inc. |
Identification of tissue-specific extragenic safe harbors for gene therapy approaches
|
|
WO2023220603A1
(en)
|
2022-05-09 |
2023-11-16 |
Regeneron Pharmaceuticals, Inc. |
Vectors and methods for in vivo antibody production
|
|
WO2023217888A1
(en)
|
2022-05-10 |
2023-11-16 |
Institut National de la Santé et de la Recherche Médicale |
Base editing approaches for correcting the cd39 (cag>tag) mutation in patients suffering from βeta-thalassemia
|
|
EP4532720A2
(en)
|
2022-05-31 |
2025-04-09 |
Regeneron Pharmaceuticals, Inc. |
Crispr interference therapeutics for c9orf72 repeat expansion disease
|
|
WO2023235725A2
(en)
|
2022-05-31 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Crispr-based therapeutics for c9orf72 repeat expansion disease
|
|
EP4544051A2
(en)
|
2022-06-24 |
2025-04-30 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression
|
|
CA3261865A1
(en)
|
2022-07-12 |
2024-01-18 |
Tune Therapeutics, Inc. |
TARGETED TRANSCRIPTIONAL ACTIVATION COMPOSITIONS, SYSTEMS AND METHODS
|
|
AU2023311964A1
(en)
|
2022-07-18 |
2025-01-30 |
Renagade Therapeutics Management Inc. |
Gene editing components, systems, and methods of use
|
|
EP4558633A1
(en)
|
2022-07-22 |
2025-05-28 |
Institut National de la Santé et de la Recherche Médicale |
Base editing approaches for correcting the ivs2-1 (g>a) mutation in patients suffering from beta-thalassemia
|
|
AU2023314808A1
(en)
|
2022-07-29 |
2025-03-20 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
|
|
EP4573200A2
(en)
|
2022-08-19 |
2025-06-25 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression
|
|
WO2024044723A1
(en)
|
2022-08-25 |
2024-02-29 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
WO2024047247A1
(en)
|
2022-09-02 |
2024-03-07 |
Institut National de la Santé et de la Recherche Médicale |
Base editing approaches for the treatment of amyotrophic lateral sclerosis
|
|
CN120239746A
(zh)
|
2022-09-19 |
2025-07-01 |
图恩疗法股份有限公司 |
用于调节t细胞功能的组合物、系统和方法
|
|
WO2024073606A1
(en)
|
2022-09-28 |
2024-04-04 |
Regeneron Pharmaceuticals, Inc. |
Antibody resistant modified receptors to enhance cell-based therapies
|
|
WO2024084025A1
(en)
|
2022-10-21 |
2024-04-25 |
Keygene N.V. |
Rna transfection in plant cells with modified rna
|
|
EP4612184A1
(en)
|
2022-11-04 |
2025-09-10 |
Regeneron Pharmaceuticals, Inc. |
Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
|
|
WO2024107765A2
(en)
|
2022-11-14 |
2024-05-23 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
|
|
CN115820603B
(zh)
*
|
2022-11-15 |
2024-07-05 |
吉林大学 |
一种基于dCasRx-NSUN6单基因特异性M5C修饰编辑方法
|
|
WO2024121354A1
(en)
|
2022-12-08 |
2024-06-13 |
Keygene N.V. |
Duplex sequencing with covalently closed dna ends
|
|
AU2023412590A1
(en)
*
|
2022-12-23 |
2025-08-07 |
Epigenic Therapeutics Pte. Ltd. |
Fusion and use thereof
|
|
WO2024163683A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist)
|
|
WO2024163678A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Fusion proteins and systems for targeted activation of frataxin (fxn) and related methods
|
|
EP4662313A1
(en)
|
2023-02-06 |
2025-12-17 |
Institut National de la Santé et de la Recherche Médicale |
Enrichment of genetically modified hematopoietic stem cells through multiplex base editing
|
|
CN116376975B
(zh)
*
|
2023-02-27 |
2024-05-14 |
中国科学院脑科学与智能技术卓越创新中心 |
激活异染色质基因的方法及应用
|
|
WO2024186890A1
(en)
|
2023-03-06 |
2024-09-12 |
Intellia Therapeutics, Inc. |
Compositions and methods for hepatitis b virus (hbv) genome editing
|
|
CN118684781A
(zh)
*
|
2023-03-21 |
2024-09-24 |
深圳赫兹生命科学技术有限公司 |
GnRH-VLP重组去势疫苗及其制备方法
|
|
WO2024201368A1
(en)
|
2023-03-29 |
2024-10-03 |
Astrazeneca Ab |
Use of inhibitors to increase efficiency of crispr/cas insertions
|
|
WO2024209000A1
(en)
|
2023-04-04 |
2024-10-10 |
Keygene N.V. |
Linkers for duplex sequencing
|
|
EP4713453A1
(en)
|
2023-05-15 |
2026-03-25 |
nChroma Bio, Inc. |
Compositions and methods for epigenetic regulation of hbv gene expression
|
|
AU2024309884A1
(en)
|
2023-06-30 |
2025-12-18 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for increasing homology-directed repair
|
|
WO2025017033A1
(en)
|
2023-07-17 |
2025-01-23 |
Institut National de la Santé et de la Recherche Médicale |
Prime editing of the -115 region in the hbg1 and/or hbg2 promoter for increasing fetal hemoglobin content in a eukaryotic cell
|
|
WO2025017030A1
(en)
|
2023-07-17 |
2025-01-23 |
Institut National de la Santé et de la Recherche Médicale |
Prime editing of the -200 region in the hbg1 and/or hbg2 promoter for increasing fetal hemoglobin content in a eukaryotic cell
|
|
KR20250016657A
(ko)
*
|
2023-07-21 |
2025-02-04 |
한국화학연구원 |
dxCas9 및 CRP 유도체를 포함하는, 표적 유전자 발현 조절 시스템 및 이의 제조방법
|
|
AR133384A1
(es)
|
2023-07-28 |
2025-09-24 |
Regeneron Pharma |
Anti-tfr:esfingomielinasa ácida para el tratamiento de la deficiencia de esfingomielinasa ácida
|
|
AU2024317483A1
(en)
|
2023-07-28 |
2026-01-29 |
Regeneron Pharmaceuticals, Inc. |
Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe disease
|
|
AU2024315073A1
(en)
|
2023-07-28 |
2026-01-22 |
Regeneron Pharmaceuticals, Inc. |
Use of bgh-sv40l tandem polya to enhance transgene expression during unidirectional gene insertion
|
|
WO2025029840A1
(en)
|
2023-07-31 |
2025-02-06 |
Tune Therapeutics, Inc. |
Compositions and methods for multiplexed activation and repression of t cell gene expression
|
|
WO2025029835A1
(en)
|
2023-07-31 |
2025-02-06 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating il-2 gene expression
|
|
WO2025038494A1
(en)
|
2023-08-11 |
2025-02-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for lymphoid cell differentiation using targeted gene activation
|
|
WO2025038646A1
(en)
|
2023-08-14 |
2025-02-20 |
Intellia Therapeutics, Inc. |
Cd70 car-t compositions and methods for cell-based therapy
|
|
WO2025038637A1
(en)
|
2023-08-14 |
2025-02-20 |
Intellia Therapeutics, Inc. |
Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2)
|
|
AU2024324870A1
(en)
|
2023-08-14 |
2026-02-12 |
Intellia Therapeutics, Inc. |
Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2)
|
|
TW202515994A
(zh)
|
2023-08-14 |
2025-04-16 |
美商英特利亞醫療公司 |
用於對ｃｄ７０進行基因修飾之組合物及方法
|
|
WO2025049524A1
(en)
|
2023-08-28 |
2025-03-06 |
Regeneron Pharmaceuticals, Inc. |
Cxcr4 antibody-resistant modified receptors
|
|
WO2025049959A2
(en)
|
2023-09-01 |
2025-03-06 |
Renagade Therapeutics Management Inc. |
Gene editing systems, compositions, and methods for treatment of vexas syndrome
|
|
WO2025059073A1
(en)
|
2023-09-11 |
2025-03-20 |
Tune Therapeutics, Inc. |
Epigenetic editing methods and systems for differentiating stem cells
|
|
WO2025064408A1
(en)
|
2023-09-18 |
2025-03-27 |
The Broad Institute, Inc. |
Compositions and methods for treating cardiovascular disease
|
|
WO2025081042A1
(en)
|
2023-10-12 |
2025-04-17 |
Renagade Therapeutics Management Inc. |
Nickase-retron template-based precision editing system and methods of use
|
|
WO2025090427A1
(en)
|
2023-10-23 |
2025-05-01 |
University Of Rochester |
Glial-targeted relief of hyperexcitability in neurodegenerative diseases
|
|
WO2025096638A2
(en)
|
2023-10-30 |
2025-05-08 |
Turnstone Biologics Corp. |
Genetically modified tumor infilitrating lymphocytes and methods of producing and using the same
|
|
WO2025117544A1
(en)
|
2023-11-29 |
2025-06-05 |
The Broad Institute, Inc. |
Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
|
|
WO2025155753A2
(en)
|
2024-01-17 |
2025-07-24 |
Renagade Therapeutics Management Inc. |
Improved gene editing system, guides, and methods
|
|
WO2025174765A1
(en)
|
2024-02-12 |
2025-08-21 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
US20250276092A1
(en)
|
2024-03-01 |
2025-09-04 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
|
|
WO2025202473A1
(en)
|
2024-03-28 |
2025-10-02 |
Revvity Discovery Limited |
A nucleic acid deaminase, a base editor and uses thereof
|
|
WO2025235388A1
(en)
|
2024-05-06 |
2025-11-13 |
Regeneron Pharmaceuticals, Inc. |
Transgene genomic identification by nuclease-mediated long read sequencing
|
|
WO2025240946A1
(en)
|
2024-05-17 |
2025-11-20 |
Intellia Therapeutics, Inc. |
Lipid nanoparticles and lipid nanoparticle compositions
|
|
WO2025250454A1
(en)
|
2024-05-28 |
2025-12-04 |
University Of Rochester |
Adeno-associated viruses evolved to specifically target human glial progenitor cells in vivo
|
|
WO2025255308A1
(en)
|
2024-06-07 |
2025-12-11 |
Intellia Therapeutics, Inc. |
Cd8 co-receptor chimeric polypeptides in tcr cell therapy
|
|
WO2025260068A1
(en)
|
2024-06-14 |
2025-12-18 |
Tune Therapeutics, Inc. |
Lipid nanoparticle formulation for delivery of nucleic acids to cells
|
|
US20250388890A1
(en)
|
2024-06-20 |
2025-12-25 |
Regeneron Pharmaceuticals, Inc. |
ASS1 Gene Insertion For The Treatment Of Citrullinemia Type I
|
|
WO2025261475A1
(zh)
*
|
2024-06-21 |
2025-12-26 |
益杰立科(上海)生物科技有限公司 |
靶向血管内皮生长因子的工程化基因转录阻抑工具及用途
|
|
WO2026006542A2
(en)
|
2024-06-26 |
2026-01-02 |
Yale University |
Compositions and methods for crispr/cas9 based reactivation of human angelman syndrome
|
|
WO2026015647A1
(en)
|
2024-07-09 |
2026-01-15 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for cell differentiation using targeted gene activation of dll4 and/or vcam1
|
|
CN121554544A
(zh)
*
|
2026-01-23 |
2026-02-24 |
成都医学院 |
一种NFT蛋白及其制备方法和应用，以及一种NusA或NusA融合蛋白的纯化方法
|